Yoshimaru et al. synthesized a negative peptide ERAP (11R-GGG-QMLSDLTLQLRQR) which could release PHB2 from BIG3 and peptide ERAP treatment enhanced tamoxifen responsiveness in ERa-positive breast cancer cells (Yoshimaru et al., 2013). Here, ESR1 is linked to breast cancer.